MEM 3454

DRUG3 trials

Sponsors

Memory Pharmaceuticals

Conditions

Alzheimer's DiseaseCognitive Impairment Associated With SchizophreniaSchizophrenia

Phase 2

Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease

CompletedNCT00454870

Memory PharmaceuticalsAlzheimer's Disease

Start: 2007-02-28End: 2007-10-31Target: 80Updated: 2008-05-06

Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia

Memory PharmaceuticalsCognitive Impairment Associated With Schizophrenia

Start: 2007-12-31Target: 160Updated: 2008-12-08

A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia Patients

Memory PharmaceuticalsSchizophrenia

Start: 2008-08-31End: 2009-04-30Target: 12Updated: 2008-07-31